Bio-Techne

Bio-Techne EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Bio-Techne (TECH) as of Oct 9, 2026 is 37.22. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 87.65 — a change of -57.53% (lower).

EV/EBIT

37.22

YoY

-57.53%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Bio-Techne is 2026 37.22 . EV/EBIT (Enterprise Value to EBIT) of Bio-Techne was 2025 87.65 . It decreases by -57.53% lower compared to the previous year.

The Bio-Techne EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
74.66 USD
Jan 1, 2020
53.27 USD
Jan 1, 2021
39.51 USD
Jan 1, 2022
30.53 USD
Jan 1, 2023
30.57 USD
Jan 1, 2024
45.36 USD
Jan 1, 2025
87.65 USD
Jan 1, 2026
37.22 USD
The Bio-Techne EV/EBIT history
YEAREV/EBITYoY
37.22-57.53%
87.65+93.22%
45.36+48.41%
30.57+0.12%
30.53-22.73%
39.51-25.83%
53.27-28.65%
74.66+8.44%
68.85-10.57%
76.99+23.66%
62.26-2.37%
63.77+8.66%
58.69+165.46%
22.11+45.75%
15.17-2.13%
15.50-0.70%
15.61-8.07%
16.98-0.06%
16.99-19.13%
21.01—
Access this data via the Eulerpool API

Bio-Techne Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Bio-Techne's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Bio-Techne's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Bio-Techne's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Bio-Techne grows earnings faster than its peers.

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

EV/EBIT (Enterprise Value to EBIT) of Bio-Techne is 37.22 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Bio-Techne changed from 87.65 to 37.22, representing a -57.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Bio-Techne with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Bio-Techne

All Key Metrics — Bio-Techne